Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study
Open Access
- 7 December 2022
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 94 (4) , 284-289
Abstract
Background Timing of disease-modifying therapy affects clinical disability in multiple sclerosis, but it is not known whether patient reported outcomes are also affected. This study investigates the relationship between treatment timing and patient-reported symptoms and health-related quality of life. Methods This was a nationwide observational cohort study of adults with relapsing multiple sclerosis, with disease onset between 2001 and 2016, and commenced on disease-modifying treatment within 4 years from disease onset. Patients commencing treatment within 0–2 years were compared with patients commencing treatment at 2–4 years. Indication bias was mitigated by propensity matching. Outcomes were patient-reported symptoms and health-related quality of life as measured by the Multiple Sclerosis Impact Scale (MSIS-29) and EuroQol-5 Dimensions-3 Level (EQ-5D). The follow-up period was 4–10 years from disease onset. Results There were 2648 patients (69% female, median age 32.8) eligible for matching. Mean follow-up time was 3.7 years. Based on 780 matched patients, each year of treatment delay was associated with a worse MSIS physical score by 2.75 points (95% CI 1.29 to 4.20), and worse MSIS psychological score by 2.02 points (95% CI 0.03 to 3.78), in the adjusted models. Among 690 matched patients, earlier treatment start was not associated with EQ-5D score during the follow-up. Conclusions Earlier commencement of disease-modifying treatment was associated with better patient-reported physical symptoms when measured using a disease-specific metric; however, general quality of life was not affected. This indicates that other factors may inform patients’ overall quality of life.Keywords
This publication has 32 references indexed in Scilit:
- Long-term effects of fingolimod in multiple sclerosisNeurology, 2015
- Subjective wellbeing, health, and ageingThe Lancet, 2015
- Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worseningMultiple Sclerosis Journal, 2014
- Real‐life impact of early interferonβ therapy in relapsing multiple sclerosisAnnals of Neurology, 2009
- Socioeconomic Inequalities in Health in 22 European CountriesNew England Journal of Medicine, 2008
- The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical)Journal of Neurology, Neurosurgery & Psychiatry, 2007
- How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scalesJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year dataActa Neurologica Scandinavica, 2005
- PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology, 2001
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001